- Home
- MAIA vs ONCY Comparison
MAIA vs ONCY Comparison
Compare MAIA & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- ONCY
- Stock Information
- Founded
- MAIA 2018
- ONCY 1998
- Country
- MAIA United States
- ONCY Canada
- Employees
- MAIA N/A
- ONCY N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- ONCY Pharmaceuticals and Biotechnology
- Sector
- MAIA Health Care
- ONCY Health Care
- Exchange
- MAIA Nasdaq
- ONCY Nasdaq
- Market Cap
- MAIA 46.7M
- ONCY 49.1M
- IPO Year
- MAIA 2022
- ONCY 1999
- Fundamental
- Price
- MAIA $1.88
- ONCY $1.17
- Analyst Decision
- MAIA
- ONCY Strong Buy
- Analyst Count
- MAIA 0
- ONCY 4
- Target Price
- MAIA N/A
- ONCY $4.33
- AVG Volume (30 Days)
- MAIA 529.1K
- ONCY 1.6M
- Earning Date
- MAIA 08-08-2025
- ONCY 07-31-2025
- Dividend Yield
- MAIA N/A
- ONCY N/A
- EPS Growth
- MAIA N/A
- ONCY N/A
- EPS
- MAIA N/A
- ONCY N/A
- Revenue
- MAIA N/A
- ONCY N/A
- Revenue This Year
- MAIA N/A
- ONCY N/A
- Revenue Next Year
- MAIA N/A
- ONCY N/A
- P/E Ratio
- MAIA N/A
- ONCY N/A
- Revenue Growth
- MAIA N/A
- ONCY N/A
- 52 Week Low
- MAIA $1.40
- ONCY $0.33
- 52 Week High
- MAIA $4.24
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- MAIA 56.41
- ONCY 75.27
- Support Level
- MAIA $1.80
- ONCY $0.71
- Resistance Level
- MAIA $2.15
- ONCY $1.31
- Average True Range (ATR)
- MAIA 0.13
- ONCY 0.12
- MACD
- MAIA 0.02
- ONCY 0.04
- Stochastic Oscillator
- MAIA 60.00
- ONCY 81.33
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.